Mannkind - MNKD - The Next Major Mover In the Drug Sector
Mannkind, MNKD, is one of the most undervalued stock in the drug sector. The company is currently engaged in talks with multiple potential “big pharma” partners for its diabetes drug, Afreeza which is in phase 3 trials. It also has several promising drugs for the treatment of various cancers in development and has already partnered on one of them.
Recent comments by management indicate that the company will obtain non-dilutive financing from a loan rather than through the sale of additional shares of stock which is one thing that has been holding the share price down.